Not yet taking people in Hollandia2. fázis
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in Mesothelioma
Key facts
- Where
- Rotterdam, HollandiaSee the site
- Phase
- 2. fázis
Where in Hollandia
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Trial code
- EU 2026-526036-38-00
- Record updated
- 2026. július 9.
- Original description
To evaluate whether co-administration of an anti-p40 antibody reduces the incidence of severe (grade ≥3) irAEs in patients receiving dual ICB with anti–PD-1 and anti–CTLA-4 antibodies.Read full original descriptionShow less
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
To evaluate whether co-administration of an anti-p40 antibody reduces the incidence of severe (grade ≥3) irAEs in patients receiving dual ICB with anti–PD-1 and anti–CTLA-4 antibodies.
Inclusion: A diagnosis of pathologically confirmed irresectable pleural mesothelioma (confirmed by histology or cytology); Age 18 years or older; ECOG performance status of 0 or 1, or a Karnofsky Performance Scale of 70 or higher; Eligible for dual ICB treatment.
Exclusion: Current use of immunomodulatory drugs within 14 days prior to initiation of ICB; Known hypersensitivity to ustekinumab; Active (mycobacterial) infection; Chronic, recurring infections.